ClinicalTrials.gg
RecruitingNCT06544837Updated May 7, 2025

Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure

An interventional study of Window of Implantation in IVF, Window of Implantation and microRNA, sponsored by Inti Labs. Recruiting at 1 site in Vietnam. Open to female participants aged 28 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Inti Labs · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
28 Years to 45 Years
Sex
Female
01

Study summary

The adjustment of the timing of embryo transfer based on the endometrial receptivity profile and transferring embryo(s) of good quality with normal chromosomes (diagnosed by Preimplantation Genetic Testing for Aneuploidy, PGT-A) are the two main causes to improve the success of assisted reproduction treatments (ART). Previously, endometrial receptivity analysis was performed on women undergoing IVF treatment through an invasive endometrial tissue biopsy. The aim of this study is to determine the clinical benefits of ORA, a novel non-invasive endometrial receptivity test that determines the optimal time for embryo transfer through a blood draw instead of an invasive endometrial tissue biopsy. It is expected to recruit 1000 couples whose embryos will be analyzed by PGT-A and/or who are going to evaluate their endometrium expression profile for endometrial receptivity. The patients will be randomized into two groups, (1) Control group : undergoing PGT-A only; (2) Study group : the undergoing both PGT-A and ORA. ART will be performed based on the results of PGT-A and/or ORA. Reproductive success, such as implantation rates (IR), pregnancy rates (PR), ongoing pregnancy rates (OGP) and live birth rates (LBR) will be tracked and compared.

Preliminary results demonstrate that both PGT-A and ORA can contribute to reproductive success, improving implantation rates in patients with implantation failure. Our hypothesis suggests that PGT-A and ORA could improve the performance of ART in infertile patients.

02

Conditions studied

  • IVF
  • Window of Implantation
  • microRNA
  • Implantation
  • Non-invasive Testing
  • Endometrial Receptivity
03

In context

Lead sponsor

Inti Labs is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Experienced implantation failure with euploid or low-level mosaic (\< 30%) embryos in the past two years.
  • Female age 28-45 years.
  • Consent to undergo a simulated cycle for non-invasive optimal implantation window testing.
  • Plan to undergo a frozen embryo transfer cycle.
  • Have at least one euploid or low-level mosaic (\< 30%) frozen blastocyst.

Exclusion criteria

Exclusion Criteria:

  • Presence of uterine cavity abnormalities that may affect implantation, such as polyps, fibroids ≧4 cm, or hydrosalpinx
  • Presence of systemic diseases that may affect reproductive techniques (e.g., diseases)
  • (BMI) over 30 kg/m²
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,000 participants (estimated)

Study arms

  • No intervention
    Control Group

    Embryo implantation according to standard procedures

  • Experimental
    ora Test Group

    Embryo implantation according to endometrial receptivity test (ora) recommendations

    Diagnostic Test: Window of Implantation

Interventions

  • Diagnostic testWindow of Implantation

    Determine the subject's window of implantation through testing and adjust the embryo implantation time

06

What researchers measure

Primary outcomes

  1. Clinical pregnancy rate

    Rate of Participants with one or more intrauterine gestational sacs after 6 weeks of estimated gestational age.

    Time frame: 6 weeks after embryo transfer

Secondary outcomes

  1. Ongoing pregnancy rate

    Rate of Participants with fetal heartbeat after 12 weeks of gestation.

    Time frame: 12 weeks after embryo transfer

  2. Live birth rate

    Rate of Participants with live birth, defined as the delivery of a live infant with signs of life after 20 weeks of gestation.

    Time frame: 20 weeks after embryo transfer

07

Study locations

1 of 1 sites recruiting
  • Hanoi Hospital
    Hanoi, Vietnam
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 9, 2024
StartActual
Jun 22, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2027
Last update
May 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06544837
Lead sponsor
Inti Labs
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Jun 22, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
May 7, 2025

Study contacts

Tiffany Wang
Contact
tiffany@intilabs.com
+886 3 6581031
Winter Hong
Contact
winterhong@intilabs.com
+886 3 6581031

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion